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Abstract
Previous studies in rat models of neurodegenerative disorders have shown disregulation of striatal synaptotagmin7 mRNA.
Here we explored the expression of synaptotagmin7 mRNA in the brains of rats with seizures triggered by the glutamatergic
agonist kainate (10 mg/kg) or by the muscarinic agonist pilocarpine (30 mg/kg) in LiCl (3 mEq/kg) pre-treated (24 h) rats, in
a time-course experiment (30 min - 1 day). After kainate-induced seizures, synaptotagmin7 mRNA levels were transiently
and uniformly increased throughout the dorsal and ventral striatum (accumbens) at 8 and 12 h, but not at 24 h, followed at
24 h by somewhat variable upregulation within different parts of the cerebral cortex, amigdala and thalamic nuclei, the
hippocampus and the lateral septum. By contrast, after LiCl/pilocarpine-induced seizures, there was a more prolonged
increase of striatal Synaptotagmin7 mRNA levels (at 8, 12 and 24 h), but only in the ventromedial striatum, while in some
other of the aforementioned brain regions there was a decline to below the basal levels. After systemic post-treatment with
muscarinic antagonist scopolamine in a dose of 2 mg/kg the seizures were either extinguished or attenuated. In
scopolamine post-treated animals with extinguished seizures the striatal synaptotagmin7 mRNA levels (at 12 h after the
onset of seizures) were not different from the levels in control animals without seizures, while in rats with attenuated
seizures, the upregulation closely resembled kainate seizures-like pattern of striatal upregulation. In the dose of 1 mg/kg,
scopolamine did not significantly affect the progression of pilocarpine-induced seizures or pilocarpine seizures-like pattern
of striatal upregulation of synaptotagmin7 mRNA. In control experiments, equivalent doses of scopolamine per se did not
affect the expression of synaptotagmin7 mRNA. We conclude that here described differential time course and pattern of
synaptotagmin7 mRNA expression imply regional differences of pathophysiological brain activation and plasticity in these
two models of seizures.
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Introduction
Synaptotagmin7 (Syt 7) is a member of the Syt family, which are
proteins characterized as essential for synaptic and extrasynaptic
membrane trafficking in the brain [1–3]. Syt 7 has been suggested
to function as a regulator of synaptic vesicle exocytosis by working
cooperatively with vesicular Syt 1 and Syt 2, based on its location
on neuronal plasma membranes [4,5]. Syt 7 protein has also been
localized on lysosomes in primary sympathetic neurons [6]. The
involvement of Syt 7 in exocytosis of lysosomes was confirmed in
Syt 7-deficient mice that exhibited impaired membrane resealing,
autoimmune myositis, and impaired insulin secretion and glucose
intolerance [7,8]. Superior cervical ganglion neurons explanted
from these mice revealed marked defects in neurite outgrowth and
arborization, suggesting that Ca
2+-dependent, Syt 7-regulated
exocytosis of late endosomes/lysosomes plays a role in the addition
of new membrane for developing neurite extensions [6].
We previously showed dopamine dependent plasticity of Syt 7
expression in hypersensitive striatum in animal models of
Parkinson’s disease [9–11]. Specifically, antiparkinsonian drugs
induced a robust increase in striatal Syt 7 mRNA levels in 6-
OHDA and reserpinized rats, two established models for
Parkinson’s disease, via a dopamine D1 receptor-linked mecha-
nism [9,10]. These results led to the hypothesis that Syt 7 may play
a significant role in the effectiveness of antiparkinsonian drugs
[9,10]. However, the exact molecular and pharmacological
mechanisms by which changes in striatal Syt 7 expression may
be involved in the dopaminergically deafferented striatum remain
largely unknown.
Given the potential importance of Syt 7 regulation in
pathological processes of brain plasticity, it would be expected
that Syt 7 may also play a key role in epileptogenesis. Systemic
administration of the convulsants, kainate (KA) or pilocarpine (PI)
causes neuronal hyperexcitation and sustained seizure activity,
which leads to excitotoxic injury, neurodegeneration, aberrant
hippocampal plasticity, and gliosis [12–14]. These changes are
followed by the development of spontaneous recurrent seizures,
reminiscent of temporal lobe epilepsy in humans [15]. Although PI
and KA both cause similar epileptic seizures and pathological
changes in the brain, they differ in their initial mode of action. PI
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(mAChR) that provokes seizures indirectly by overstimulation of
glutamatergic neurons of the cortex [16]. Once triggered by the
excessive cholinergic activity, seizures are propagated by the
sustained cortical glutamatergic overactivity. In the PI model, LiCl
pre-treatment is given in order to decrease the threshold for the
onset of seizures triggered by PI. In contrast, KA is agonist of some
subtypes of glutamate receptors (GluR), and thus directly
overstimulates the cortex by mimicking cortical glutamatergic
overactivity [17].
In order to study the function of Syt 7 in seizures, we
investigated whether epileptic seizures induced with either LiCl/PI
or KA would affect the levels of Syt 7 mRNAs in the rat brain. In
this study, we found that PI and KA induced differential patterns
of upregulation of striatal Syt 7 mRNA. Furthermore, in rats with
PI-induced seizures, the muscarinic antagonist, scopolamine
(SCO), modified the pattern of striatal Syt 7 mRNA expression.
Results
Changes in Syt 7 mRNA levels in animals with KA-
induced seizures
We examined a detailed time-course of the Syt7 mRNA signal
for groups of rats that were killed 30 min, 4 h, 8 h, 12 h, and 1
day after the beginning of KA-evoked grade IV–V seizures [18].
In the dorsal striatum and ventral striatum (nucleus accumbens),
we found a significant augmentation (one-way ANOVA followed
by Tukey multiple-comparison test, P,0.05) of Syt 7 mRNA
signal at 8 h and 12 h after the onset of KA-induced seizures as
compared to controls (Figs. 1 and 2). In addition, KA induced a
distinctive pattern of elevation of Syt 7 mRNA signal in several
extrastriatal brain regions at 24 h post injection (Fig. 1). At 24 h,
somewhat variable pattern of significant upregulation (one-way
ANOVA followed by Tukey multiple-comparison test, P,0.05)
was evident in the outer layers of the cerebral cortex, pyriform
cortex, amigdala nuclei and the septum, while in the cingular
cortex and thalamic nuclei the upregulation was not observed in
all of the animals and it did not reach statistical significance (Figs. 1
and 2). In the rostral hippocampus, we observed a progressive
significant decline (one-way ANOVA followed by Tukey multiple-
comparison test, P,0.05) of Syt 7 mRNA signal t hat was most
prominent at later time points (Figs. 1 and 2). However, in the
dorsal hippocampus, a patchy upregulation pattern was observed
in CA1, CA2 and CA3 regions of some of the animals, but again
only at 24 h after the onset of grade IV–V seizures (not shown).
Changes in Syt 7 mRNA levels in animals with LiCl/PI-
induced seizures
In the time-course experiment for LiCl/PI-induced seizures, Syt
7 mRNA levels were determined at 30 min, 4 h, 8 h, 12 h, and
approximately 1 day (20 h) after the onset of grade IV–V seizures.
In the ventromedial striatum, LiCl/PI treatment induced a
significant augmentation (one-way ANOVA followed by Tukey
multiple-comparison test, P,0.05) of Syt 7 mRNA signal at 8, 12,
and 20 h groups as compared to the control group (Figs. 3 and 4).
In contrast, in the dorsolateral striatum, LiCl/PI significantly
downregulated (one-way ANOVA followed by Tukey multiple-
comparison test, P,0.05) the Syt 7 mRNA signal at 8, 12 and 20 h
as compared to the control group (Figs. 3 and 4). Significant
downregulation (one-way ANOVA followed by Tukey multiple-
comparison test, P,0.05) of Syt 7 mRNA levels was also observed
at later time points in other brain regions: piriform and cingulate
cortex, thalamus and dentate gyrus, CA3, CA2, CA1 regions of
hippocampus (Fig. 4). There were no significant differences (paired
Student’s t-test, p.0.05) of corresponding Syt 7 mRNA signals
between two control groups, saline-only and LiCl-only treated
animals, in any of the observed brain regions (Fig. 4).
Effect of scopolamine post-treatment on Syt 7 mRNA
levels in animals with seizures induced with LiCl/PI
The treatment with 2 mg/kg, but not with 1 mg/kg SCO
abolished the LiCl/PI induced grade IV seizures in two out of four
animals. In these animals the Syt 7 mRNA expression pattern
(observed 12 h after the onset of seizures) was similar to controls
(Fig. 5; one-way ANOVA followed by Tukey multiple-comparison
test, P,0.05). In the remaining two animals from this group
further seizure activity was attenuated by post-treatment with
2 mg/kg SCO, Syt 7 mRNA was upregulated throughout the
dorsal and ventral striatum in a manner similar to that in KA
group (Fig. 5). By contrast, in animals post-treated with 1 mg/kg
of SCO at the onset of LiCl/PI-induced seizures, the seizures
continued unabated during the 1 h observation period with
apparently unchanged intensity. In these animals Syt 7 mRNA
was upregulated only in the ventromedial striatum (as observed
12 h after the onset of seizures) in a manner similar to that
observed in the LiCl/PI group of animals with seizures without
scopolamine post-treatment (Fig. 5). There were no significant
differences (one-way ANOVA followed by Tukey multiple-
comparison test, P,0.05) of corresponding Syt 7 mRNA ROD
signals between different control groups (i.e. animals treated with
only saline, LiCl, scopolamine 1 mg/kg or 2 mg/kg) (Fig. 5).
Figure 1. Time-course of Syt 7 mRNA expression in midbrain
and forebrain after kainic acid-induced seizures or saline
treatment. Animals were sacrificed at 30 min, 4, 8, 12, and 24 h after
the injection.
doi:10.1371/journal.pone.0036114.g001
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In the present study, we used in situ hybridization with a Syt 7
gene specific probe to investigate whether epileptic seizures
induced by PI or KA would affect the levels of Syt 7 mRNA in
the brain and to investigate some of the possible pharmacological
mechanisms underlying the seizure-induced changes of striatal Syt
7 mRNA expression. To the best of our knowledge this study
demonstrates for the first time that brain Syt 7 mRNA levels could
be strongly affected in rat models of seizures. After KA-induced
seizures, Syt 7 mRNA levels were transiently and uniformly
increased throughout the striatum, followed by somewhat variable
upregulation within different parts of the cerebral cortex, amigdala
and thalamic nuclei, the caudal (but not rostral) hippocampus and
the lateral septum. By contrast, after PI-induced seizures, there
was a more prolonged increase of Syt 7 mRNA levels, but only in
the ventromedial striatum, while in the dorsolateral striatum and
in some other of the above mentioned brain regions there was
concomittant downregulation of Syt 7 mRNA levels to below the
basal levels.
In both seizure models, the striatum stood out as the region
where the changes in Syt 7 mRNA expression appeared first. It is
well known that the striatum regulates motor coordination and is
connected with cortical and subcortical structures that are
activated during seizures [19,20]. The striato–nigral GABAergic
neurons may be important in the seizure activity formation, since
the activation of these neurons by NMDA agonists or GABA
antagonists block seizures [16,21]. The striatum might serve as as
relay or gating station for the propagation of seizures [22], a role
consistent with the known functional connections of the basal
ganglia with thalamo-cortical and the limbic system. In our
experiments, KA-induced seizures upregulated Syt 7 mRNA
uniformly across the striatum and nucleus accumbens, whereas PI-
evoked seizures upregulated Syt 7 mRNA only within the
ventromedial striatum. Moreover, we found a downregulation of
Syt 7 mRNA signal in the dorsolateral striatum at 12 h after the
beginning of PI-induced seizures. The reason for these differences
between the two models likely relates to the different receptor
mechanisms by which PI and KA induce seizures. KA directly
stimulates kainate and a9-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) receptors, whereas PI causes neuronal
hyperexcitation via muscarinic receptor activation. All three types
of receptors have been localized in the striatum, including all five
muscarinic subtypes, M1-M5 [23–25]. Striatal AMPA, kainate,
and muscarinic receptors are expressed on intrinsic postsynaptic
neurons [24], which contain soma in the striatum. These neurons
comprise mainly GABAergic medium-spiny neurons that project
to substantia nigra reticulata and globus pallidus, as well as
cholinergic interneurons. Thus, PI and KA, at least to a certain
extent, may induce Syt 7 mRNA expression in the striatum by
directly stimulating these receptors. As evidenced by many studies,
KA causes the upregulation of numerous genes in hippocampus
directly by stimulation of glutamate receptors [26]. We have also
found the upregulation of Syt 7 mRNA after KA-induced seizure
in some of epileptogenic regions normally affected by glutamate
transmission, such as the caudal hippocampus, amigdala, pyriform
cortex and the thalamus. However, our results do not exclude the
possibility that Syt 7 mRNA expression may be regulated by
mechanisms other than by direct stimulation of glutamate and/or
muscarinic receptors. For example, the upregulation of Syt 7
mRNA in KA model of seizures that occurred in many regions
with strong dopaminergic innervations, such as striatum and
cingular cortex, may be tentatively explained also by dopaminer-
gic hyperactivity during seizures. Indeed, it has been reported that
induction of seizure activity by both KA and PI can affect gene
expression in striatal neurons indirectly by increasing striatal
dopamine release [27–29]. PI induces striatal Fos protein
Figure 2. Levels of Syt 7 mRNA expression in different brain regions after kainic acid-induced seizures. ROD (relative optical density,
means 6 SEM) *significantly different from saline treated animals (one-way ANOVA followed by Tukey multiple-comparison test, P,0.05).
doi:10.1371/journal.pone.0036114.g002
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can be almost completely prevented by of the D1 antagonist,
SCH-23390 [30]. Striatal D1 receptor activation causes the
upregulation of Fos and Jun proteins which bind AP-1 transcrip-
tion complex-binding consensus sequences in promoter areas of
several genes [31,32]. D1 receptor stimulation also causes the
phosphorylation of other transcription factors, such as cAMP
response element-binding protein (CREB). Interestingly, an
important role of the CREB/CRE transcriptional pathway has
been recently suggested to mediate the expression of genes
responsible for the protection against oxidative stress-mediated
neuronal cell death in the PI model [33]. A search of the
GeneBank database indicates that the Syt 7 gene actually possesses
both the cAMP-response element binding protein (CRE) and AP-1
transcription complex-binding consensus sequences in its promot-
er area, which bind CREB and Fos/Jun proteins. Syt 7 expression
in striatum has previously been shown to be regulated by
dopamine via D1, but not D2, receptors [9,10]. Namely, in
dopamine deprived striatum of hemiparkinsonic rats, striatal Syt 7
mRNA also attained peak levels between 8 and 12 h after D1
receptor stimulation [9]. This suggests that in PI- and KA induced
seizures, Syt 7 mRNA upregulation in the striatum may be
provoked by increased striatal dopamine release during seizures.
Moreover, the possibility of dopaminergic involvement may be
inferred also by considering the longstanding hypothesis of an
antagonistic balance between dopamine and acetylcholine in
normal striatal function [34]. For example, cholinergic transmis-
sion via interaction with muscarinic receptors, inhibits basal and
D1 receptor-stimulated striatal gene expression and cAMP
formation [35,36]. Taking into consideration the possibility of
the above mentioned dopaminergic-cholinergic interactions, our
results suggest that the PI-could prevent the effect of excessive
release of endogenous dopamine during seizures on Syt 7 mRNA
upregulation or even induce downregulation of Syt 7 mRNA in
the dorsolateral striatum.
To further explore the proposed cholinergic mechanism of
seizure-induced changes of striatal Syt 7 mRNA expression, we
performed additional experiments with the aim to inhibit the effect
of PI on muscarinic receptors by SCO post-treatment. A high
systemic dose of SCO (2 mg/kg), given at the onset of PI-induced
seizures, completely prevented the upregulation of Syt 7 mRNA in
ventromedial striatum and nucleus accumbens, but only in rats in
which SCO also completely abolished PI-induced seizures. In
these animals, the pattern of striatal Syt 7 mRNA levels was similar
to the pattern in control rats without seizures. In contrast, in
animals in which the same high dose of SCO did not inhibit the
seizures, Syt 7 mRNA showed robust upregulation across the
whole striatum (i.e., not limited to the ventromedial striatum and
nucleus accumbens, as seen in animals with PI-induced seizures).
It may be possible that in these animals, the propagation of
seizures was sustained by glutamatergic mechanisms, while SCO
prevented further stimulation of muscarinic receptors by PI.
Interestingly, the striatal expression pattern in these animals was
identical to that induced by KA-evoked seizures. This suggests that
in the PI model of seizures, striatal Syt 7 mRNA upregulation may
be opposed by the stimulation of muscarinic receptors. By this
rationale, SCO given at the onset of seizures could attenuate the
inhibiting effect of PI on seizure-evoked upregulation of syt 7
mRNA within the dorsolateral striatum. Why the same effect of
SCO did not occur also in the ventromedial striatum, remains to
be determined. Moreover, to better resolve this issue and to
distinct between the possible direct or indirect involvement of the
striatal muscarinic receptors on the expression of Syt 7 mRNA,
intrastriatal stereotaxic injection of SCO (e.g. via previously
implanted intrastriatal catheters) at the onset of PI- and KA-
induced seizures, should be performed in the future.
Compared to controls, KA-induced seizures downregulated Syt
7 mRNA only in the rostral hippocampus, whereas PI diminished
the Syt 7 mRNA expression in hippocampus, cingulate cortex and
thalamus. In all of these brain regions, the greatest downregulation
occurred at about one day after the onset of seizures, possibly
indicating the loss of nerve cells or a general transcriptional
attenuation during the process of epileptogenesis [12,37].
A robust upregulation of numerous genes caused by seizure
activity could be directly involved in neuronal plasticty associated
with epileptogenesis [26,38–40], while others are probably
implicated in neurodegeneration and gliosis caused by a sustained
seizure-related neuronal hyperexcitation [26]. In our experiment,
massive upregulation of Syt 7 mRNA within epileptogenic regions
occurred only after seizures induced with KA. Future studies
should determine whether differential upregulation of Syt 7
mRNA confers some important differences in these two models
of epileptogenesis. Based on current knowledge about Syt 7
function in the brain, altered Syt 7 expression could affect the Syt
1/Syt2 regulated synaptic vesicle exocytosis resulting in changed
synaptic transmission [4,5], or it could alter the exocytosis of late
endosomes/lysosomes enabling the addition of new membrane to
form new extensions [6]. Based on our findings, striatal plasticity
could be differentially affected in these two models of seizures.
Figure 3. Time-course of Syt 7 mRNA expression in midbrain
and forebrain after pilocarpine-induced seizures. Animals were
killed 30 min, 4, 8, 12, and 20 h after the injection, and two groups of
animals received saline injection (Sal) or LiCl.
doi:10.1371/journal.pone.0036114.g003
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caused differential changes in the expression of Syt 7 mRNA in the
brain, thus demonstrating complex regulatory mechanisms for
striatal Syt 7 mRNA expression in seizures. It appears that the
stimulation of muscarinic receptors with PI opposes, rather than
stimulates the upregulation of striatal Syt 7 mRNA. We speculate
that in both models of seizures, striatal upregulation of Syt 7
mRNA may be induced indirectly, possibly by the seizure-induced
increases in striatal glutamatergic/dopaminergic transmission.
The differential pattern of striatal Syt 7 mRNA upregulation
may thus indicate cholinergic inhibition of striatal Syt 7 mRNA
expression. Based on the possible role of Syt 7 in membrane
reshaping and/or the regulation of synaptic transmission, this
study also suggests differential plasticity within epileptogenic brain
regions in kainate and pilocarpine models of seizures. This may
differentialy affect the neuronal loss, reactive gliosis, and axonal
sprouting that preceed the emergence of chronic spontaneous
recurrent seizures [15] and implies at least subtle differences in
these two models of human acquired epilepsy. Future progress in
the understanding of Syt 7 regulation may thus shed new light on
epileptogenesis and its potential treatment.
Methods
Animals
Adult male Wistar rats (290–330 g) were maintained on a 12 hr
light/dark cycle (lights on 07:00–19:00) in a temperature-
controlled colony room at 22–24uC with free access to rodent
pellets and tap water. Subjects were handled according to the NIH
Guide for the Care and Use of Laboratory Animals and all
experiments were carried out in accordance with the European
Council Directive of November 24th, 1986 (86/609/EEC).
Drugs
The following drugs were used: lithium chloride (LiCl),
pilocarpine hydrochloride (PI), scopolamine hydrobromide
(SCO) and kainic acid; (KA; 2-Carboxy-3-carboxymethyl-4-
isopropenylpyrrolidine hydrate), all purchased from Sigma, St.
Louis, MO, USA. All drugs were dissolved in 0.9% saline (Sal) and
were administered intraperitonealy (i.p.) in a volume of 1 ml/kg.
Drug solutions were freshly prepared no more than 30 min before
the injections.
Behavioral observation
The behavior was recorded by a trained investigator that was
not aware of the treatments. The rats were put in individual
transparent cages (48 cm620 cm623 cm). By behavioral obser-
vation we aimed to select only the animals that developed Racine
grade IV–V seizures [18]. We therefore ranked seizures as follows:
2 absent, + short bursts of convulsive activity (forelimb clonus
with rearing, i.e. Racine grade IV), ++ status epilepticus
(pronounced and prolonged convulsive activity, loss of balance
and falling, i.e. Racine grade V).
Time-course of Syt 7 mRNA expression in PI- and KA-
induced epileptic seizures
In a time-course study, groups of four animals were sacrificed at
different time points (30 min, 4 h, 8 h, 12 h and approximately 1
day (20–24 h) after the beginning of grade IV–V seizures
according to the Racine scale induced by KA or LiCl/PI. In
KA experiment, animals were treated with 10 mg/kg of kainic
acid. The behavior during the ‘‘latent’’ period was similar, with
few distinctive characteristics, depending on the seizure-inducing
agent. For example, PI induced characteristic yawning-like oral
dyskinesia, while KA in our hands induced more frequent wed-dog
Figure 4. Levels of Syt 7 mRNA expression in different brain regions after pilocarpine-induced seizures. VM-ventromedial striatum; DL-
dorsolateral striatum. ROD (relative optical density, means 6 SEM) *significantly different from the same brain region of saline treated animals (one-
way ANOVA followed by Tukey multiple-comparison test, P,0.05).
+significantly different from the dorsolateral striatum of saline treated animals
(one-way ANOVA followed by Tukey multiple-comparison test, P,0.05).
doi:10.1371/journal.pone.0036114.g004
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(rearing with forelimb clonus) with the onset in about 60 min. In
control experiment a group four animals received control injection
of Sal and were killed after 9 h (we took in the account the
additional ‘‘latent’’ period of about 60 min before the start of
grade IV–V seizure activity, as observed in the corresponding
experimental 8 h group with KA-induced seizures). In the LiCl/PI
experiment, animals were pretreated with LiCl (3 mEq/kg) 24 h
before the injection of PI (30 mg/kg). Grade IV–V seizures started
about 20 min after the injection of PI. Control animals in this
experiment were pretreated with LiCl (3 mEq/kg) 24 h before the
injection of Sal and were sacrificed 8 h and 20 min h after the
injection of Sal (1 ml/kg) (we took in the account the additional
‘‘latent’’ period of about 20 min before the start of grade IV–V
seizure activity, as observed in the corresponding experimental 8 h
group with LiCl/PI-induced seizures). After injection of the
seizure-inducing agent (or control injection of Sal) the animals
were housed in individual cages and observed for 2 h.
Scopolamine effects on Syt 7 mRNA expression in PI-
induced seizures
For assessment of sistemicaly applied scopolamine post-treat-
ment effects on Syt 7 mRNA expression in PI-induced seizures,
animals were divided into seven groups. The first group (n=4)
received Sal injection (1 ml/kg) and served as the control group.
The second group (n=4) received LiCl (3 mEq/kg) 24 h before
Sal (1 ml/kg) and also served as a control group. Animals from
these control groups were killed 12 h after the injection of Sal. The
third group (n=4) was pretreated with LiCl (3 mEq/kg) 24 h
before the injection of PI (30 mg/kg). All the animals in this group
developed grade IV–V epileptic seizures approximately 20 min
after the injection of PI and were sacrificed 12 h after the
beginning of seizures. The fourth group (n=4) was pretreated with
LiCl (3 mEq/kg) 24 h before the injection of PI (30 mg/kg). When
animals from this group started to display first signs of grade IV
seizures, they received systemic injection of SCO (2 mg/kg).
Group five (n=4) received the same treatment as group four,
except for receiving a lower dose of SCO (1 mg/kg)4. Group six
(n=3) received SCO (2 mg/kg) 24 h after the pre-treatment with
LiCl (3 mEq/kg) and group seven (n=3) received SCO (1 mg/kg)
24 h after the pre-treatment with LiCl (3 mEq/kg). Animals from
groups four, five, six and seven were killed 12 h after the injection
of SCO. After injection of the seizure-inducing agent (or control
injection of SCO) the animals were housed in individual cages and
monitored for 2 h for the presence or absence of grade IV–V
seizures.
Brain preparation and in situ hybridization
histochemistry
The brains were removed and quickly frozen on dry ice.
Coronal sections (10 mm) were cut through the neostriatum and
hippocampus using a cryostat and thaw mounted onto microscope
slides. The sections were then fixed in 4% phosphate-buffered
paraformaldehyde, washed in phosphate-buffered saline, dehy-
drated in 70% ethanol, and stored in 95% ethanol at +4uC until
used for in situ hybridization histochemistry as previously described
in detail [41]. The sections were incubated with 39 end
35S-
labelled oligodeoxyribonucleotide antisense probes (45 bases long)
complementary to the rat Syt 7 mRNA (bases encoding 300–344,
sequence 5=9CCG AGT CTG GCG TGC CCA CCG TCT
CCA AGG AGT TCT TGT AGC GTT-39: the probe that
recognizes all Syt 7 splicing variants), GenBank accession number
U20106. Air dried sections were incubated with
35S-labeled probe
in hybridization buffer containing 46SSC (16SSC is made out of
150 mM sodium chloride and 15 mM sodium citrate), 50%
deionized formamide, 50 mM sodium phosphate (pH 7.0), 56
Denhardt’s solution, 100 mg/ml polyadenylic acid, 10% dextran
sulfate and 40 mM dithiothreitol. The oligodeoxynucleotide
probes were labeled by incubation for one hour at 36uC with
[35S]-deoxyadenosine 59(-a-thio) triphosphate ([35S]-dATP;
1000–1500 Ci/mmol; DuPont NEN, Life Science Products Inc.,
Boston) and terminal deoxynucleotidyl transferase enzyme (Pro-
mega, Madison, WI, USA). The labeled probes were purified
using spin columns with Sephadex G50. Specific activities of the
labeled probes ranged from 55 to 150610
3 d.p.m./ml. Hybridiza-
tion buffer with labeled probe was applied to each slide and
incubated for 16 hr at 42uC in a humid chamber. Washing was
Figure 5. Effect of scopolamine on striatal Syt 7 mRNA
expression after pilocarpine treatment. Two groups of animals
received injection of 1 mg/kg (PI/SCO1) or 2 mg/kg (PI/SCO2) of
scopolamine after displaying the first signs of pilocarpine-induced
seizures. Epileptic seizures were either prevented (PI/SCO2) or were not
prevented (PI/SCO2 seizure) by scopolamine (2 mg/kg). Another three
groups received either saline (Sal), LiCl, or pilocarpine together with LiCl
(PI). All animals were killed 12 h after the treatment. A) Representative
autoradiograms showing striatal Syt 7 mRNA expression after different
treatments. B) ROD measurements (means 6 SEM) showing striatal
levels of Syt 7 mRNA expression. VM-ventromedial striatum; DL-
dorsolateral striatum. *significantly different that ROD measured in
the same brain region of saline treated animals (one-way ANOVA
followed by Tukey multiple-comparison test, P,0.05).
+significantly
different from ROD measured in dorsolateral striatum of saline treated
animals (one-way ANOVA followed by Tukey multiple-comparison test,
P,0.05).
doi:10.1371/journal.pone.0036114.g005
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at 55uCi n1 6SSC. The sections were then quickly dipped in 0.16
SSC and dehydrated through 50%, 70%, and 98% ethanol. Air
dried hybridized sections were exposed to X-ray film (Scientific
Imaging Film X-Omat
TM AR, Kodak, Rochester, NY) that were
exposed for 2–3 weeks and developed using standard darkroom
techniques. The specificity of the probe used in this study was
confirmed by the almost complete disappearance of the autora-
diographic signal when radiolabeled probe was hybridized in the
presence of 100-fold excess of unlabeled probes (data not shown).
Image analysis
The Syt 7 hybridization signal was analyzed using densitometry
with MCID, M4 image analyzer (Imaging Research Inc., Canada)
in the manually outlined regions of the ventromedial and
dorsolateral striatum, thalamus, piriform and cingulate cortex,
and hippocampal subregions (CA1, CA2, CA3 and dentate gyrus
(DG)). Relative optical density (ROD) measurements in the
striatum were performed on three sections of each animal.
Nonspecific background signal, defined as the ROD of parts of
the film without hybridization signal, was subtracted from the
ROD measurements. In situ hybridization data was assessed with
one-way analysis of variance (ANOVA) followed by Tukey
multiple comparison test. In the experiments with PI, paired
Student’s t-test was performed to evaluate the difference by
comparing ROD measurements of two control groups, saline and
LiCl treated animals. All data are expressed as means 6 S.E.M.
with statistical significance set at P,0.05.
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